Navigation Links
Valeant to Acquire Polish Dermatology Company
Date:5/8/2009

ALISO VIEJO, Calif., May 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced that it has acquired EMO-FARM Ltd., a privately held company located in Poland for approximately $28 million. The transaction expands the base for Valeant in Poland into multiple therapeutic categories. EMO-FARM has a strong expertise in topical products and brings with it a portfolio of currently marketed products and additional products under registration. As part of the transaction, Valeant will also acquire a state-of-the-art 13,000 square foot manufacturing plant completed earlier this year that specializes in gels, creams and ointments. Current annualized revenues are approximately $12 million.

"The acquisition of EMO-FARM is consistent with our business plan strategy," stated J. Michael Pearson, chairman and chief executive officer. "We now have a platform from which we can launch various topical products including our dermatology pipeline and become a premier dermatology company in the countries in which we operate The combination of an established portfolio of products, an anti-infective topical compound we plan to launch in 2010, and a cGMP-ready plant that equips us with new manufacturing capabilities, provides us with a solid dermatology opportunity in Poland, and eventually, throughout Central Europe."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the future growth in Valeant's European dermatology franchise, the impact of the EMO-FARM Ltd. acquisition on Valeant's business, the timing and potential success of registration and the approval of product candidates. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to our ability to successfully integrate the EMO-FARM assets, risks and uncertainties relating to the clinical development of product candidates, regulatory approval processes, the potential that competitors may bring to market products or treatments that are more commercially attractive than existing or future EMO-FARM products, and other risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. These risks are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements and undue reliance should not be placed on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
2. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
3. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
4. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
10. JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares
11. Teikoku Pharma USA Acquires Travanti Pharma Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: